Read our insights on what’s happening in the industry today.
Although the diversity of Africa is often cited, the full extent is still not well understood. As we learn more, the true potential of the continent for clinical research to address ongoing public health issues becomes apparent.
The dynamic nature of infectious disease epidemiology requires diligent surveillance to ensure clinical trials of vaccines and treatments can successfully recruit and account for changing seroprevalence and new variants.
Q&A From Our Webinar — Africa’s Potential for Clinical Research: Population Diversity, Expanding Therapeutic Area Expertise and Long-Standing Stakeholder Engagement
In our recent webinar, our panel of esteemed speakers broke stereotypes about Africa, discussed research-related trends and highlighted how clinical trials could benefit from the continent’s strengths.
Achieving cultural competency is increasingly important in our global community, especially to reach the populations who would most benefit from research. In this blog post, we discuss this importance as well as examples of successful community engagement.
New Horizons for TB Vaccine Research Involve Early Awareness, Coordinated Efforts and Equitable Access: Thoughts from the 6th Annual Global Forum on TB Vaccines
Several FHI Clinical team members attended the 6th Annual Global Forum on TB Vaccines. Based on their conversations and session attendance, they provide their thoughts on the future of tuberculosis prevention and vaccine development.
As researchers, we rely on the willingness of people to participate in our studies, and participant recruitment and retention continue to be one of the biggest challenges. There are numerous reasons for this, some that we can address and others that we might just have to accept.
In the fall of 2021, a small team from FHI Clinical headed to Liberia to meet the FHI Clinical PREVAIL network team. Upon their return from visiting Liberia and each of the network sites, we asked the team some questions about the trip and their accomplishments.
The FHI Clinical team is thrilled to support the development of multiple COVID-19 therapies that offer patients safe, effective treatment options during the ongoing pandemic and beyond.